aluates Reports

$ 0.0

Automative

Global Duchenne Muscular Dystrophy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Published Date: July 2025

Report Code: QYRE-Auto-12K736

Global Duchenne Muscular Dystrophy Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027

BUY CHAPTERS

Global Duchenne Muscular Dystrophy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031

Code: QYRE-Auto-12K736

Report

July 2025

Pages:128

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

PTC Therapeutics

Sarepta Therapeutics

Pfizer Inc

Bristol–Myers Squibb

Italfarmaco S.p.A.

Santhera Pharmaceuticals

Duchenne Muscular Dystrophy Market Size

In 2024, the global market size of Duchenne Muscular Dystrophy was estimated to be worth US$ 2267 million and is forecast to reach approximately US$ 25740 million by 2031 with a CAGR of 42.1% during the forecast period 2025-2031.

Duchenne Muscular Dystrophy Market

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys" respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.

North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.

In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy.

The Duchenne Muscular Dystrophy market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Duchenne Muscular Dystrophy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Duchenne Muscular Dystrophy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.

Scope of Duchenne Muscular Dystrophy Market Report

Report Metric	Details
Report Name	Duchenne Muscular Dystrophy Market
Forecasted market size in 2031	approximately US$ 25740 million
CAGR	42.1%
Forecasted years	2025 - 2031
Segment by Type	Exondys 51 Emflaza Translarna
Segment by Application	Hospitals Clinics Home Care
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Duchenne Muscular Dystrophy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Duchenne Muscular Dystrophy sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.

FAQ for this report

What is the Duchenne Muscular Dystrophy Market size in 2031?

Ans: The Duchenne Muscular Dystrophy Market size in 2031 will be approximately US$ 25740 million.

What is the Duchenne Muscular Dystrophy Market share by type?

Ans: In terms of product, Exondys 51 is the largest segment, with a share over 55%.

Who are the main players in the Duchenne Muscular Dystrophy Market report?

Ans: The main players in the Duchenne Muscular Dystrophy Market are Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals

What are the Application segmentation covered in the Duchenne Muscular Dystrophy Market report?

Ans: The Applications covered in the Duchenne Muscular Dystrophy Market report are Hospitals, Clinics, Home Care

What are the Type segmentation covered in the Duchenne Muscular Dystrophy Market report?

Ans: The Types covered in the Duchenne Muscular Dystrophy Market report are Exondys 51, Emflaza, Translarna

1 Study Coverage

1.1 Duchenne Muscular Dystrophy Product Introduction

1.2 Market by Type

1.2.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type (2020 VS 2024 VS 2031)

1.2.2 Exondys 51

1.2.3 Emflaza

1.2.4 Translarna

1.3 Market by Application

1.3.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Application (2020 VS 2024 VS 2031)

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Home Care

1.4 Study Objectives

1.5 Years Considered

2 Executive Summary

2.1 Global Duchenne Muscular Dystrophy Market Size Estimates and Forecasts

2.1.1 Global Duchenne Muscular Dystrophy Revenue 2020-2031

2.1.2 Global Duchenne Muscular Dystrophy Sales 2020-2031

2.2 Duchenne Muscular Dystrophy Market Size by Region: 2024 Versus 2031

2.3 Duchenne Muscular Dystrophy Sales by Region (2020-2031)

2.3.1 Global Duchenne Muscular Dystrophy Sales by Region: 2020-2025

2.3.2 Global Duchenne Muscular Dystrophy Sales Forecast by Region (2026-2031)

2.3.3 Global Duchenne Muscular Dystrophy Sales Market Share by Region (2020-2031)

2.4 Duchenne Muscular Dystrophy Market Estimates and Projections by Region (2026-2031)

2.4.1 Global Duchenne Muscular Dystrophy Revenue by Region: 2020-2025

2.4.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Region (2026-2031)

2.4.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2020-2031)

3 Market Segments

3.1 Breakdown Data by Type

3.1.1 Global Duchenne Muscular Dystrophy Sales by Type (2020-2031)

3.1.1.1 Global Duchenne Muscular Dystrophy Sales Volume by Type (2020-2031)

3.1.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2031)

3.1.2 Global Duchenne Muscular Dystrophy Revenue by Type (2020-2031)

3.1.2.1 Global Duchenne Muscular Dystrophy Revenue by Type (2020-2031)

3.1.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2020-2031)

3.1.3 Duchenne Muscular Dystrophy Average Selling Price (ASP) by Type (2020-2031)

3.2 Breakdown Data by Application

3.2.1 Global Duchenne Muscular Dystrophy Sales by Application (2020-2031)

3.2.1.1 Global Duchenne Muscular Dystrophy Sales Volume by Application (2020-2031)

3.2.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2031)

3.2.2 Global Duchenne Muscular Dystrophy Revenue by Application (2020-2031)

3.2.2.1 Global Duchenne Muscular Dystrophy Revenue by Application (2020-2031)

3.2.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2020-2031)

3.2.3 Duchenne Muscular Dystrophy Average Selling Price (ASP) by Application (2020-2031)

3.3 by Type and by Application Crossing Analysis

3.3.1 Exondys 51 of Duchenne Muscular Dystrophy Revenue Market Share by Application

3.3.2 Emflaza of Duchenne Muscular Dystrophy Revenue Market Share by Application

3.3.3 Translarna of Duchenne Muscular Dystrophy Revenue Market Share by Application

4 Global Duchenne Muscular Dystrophy by Manufacturers

4.1 Global Top Duchenne Muscular Dystrophy Manufacturers by Sales (2020-2025)

4.1.1 Global Duchenne Muscular Dystrophy Sales by Manufacturer (2020-2025)

4.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Manufacturer (2020-2025)

4.2 Global Top Duchenne Muscular Dystrophy Manufacturers by Revenue (2020-2025)

4.2.1 Global Duchenne Muscular Dystrophy Revenue by Manufacturer (2020-2025)

4.2.2 Global Duchenne Muscular Dystrophy Revenue Share by Manufacturer (2020-2025)

4.3 Global Duchenne Muscular Dystrophy Price by Manufacturer (2020-2025)

4.4 Competitive Landscape

4.4.1 Key Duchenne Muscular Dystrophy Manufacturers Covered: Ranking by Revenue

4.4.2 Global Duchenne Muscular Dystrophy Market Concentration Ratio (CR5 and HHI) & (2020-2025)

4.4.3 Global Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

4.5 Global Duchenne Muscular Dystrophy Manufacturing Base Distribution, Product Type

4.5.1 Duchenne Muscular Dystrophy Manufacturers Manufacturing Base Distribution, Headquarters

4.5.2 Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Market

4.5.3 Manufacturers Duchenne Muscular Dystrophy Product Type and Application

4.5.4 Exondys 51 Market Sales of Duchenne Muscular Dystrophy by Manufacturer

4.5.5 Emflaza Market Sales of Duchenne Muscular Dystrophy by Manufacturer

4.5.6 Translarna Market Sales of Duchenne Muscular Dystrophy by Manufacturer

4.6 Manufacturers Mergers & Acquisitions, Expansion Plans

5 Company Profiles

5.1 Sarepta Therapeutics

5.1.1 Sarepta Therapeutics Company Information

5.1.2 Sarepta Therapeutics Description, Business Overview

5.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Products Offered

5.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2020-2025)

5.1.5 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales by Product in 2024

5.1.6 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales by Application in 2024

5.1.7 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales by Geographic Area in 2024

5.1.8 Sarepta Therapeutics Recent Developments

5.2 PTC Therapeutics

5.2.1 PTC Therapeutics Company Information

5.2.2 PTC Therapeutics Description, Business Overview

5.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Products Offered

5.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2020-2025)

5.2.5 PTC Therapeutics Duchenne Muscular Dystrophy Sales by Product in 2024

5.2.6 PTC Therapeutics Duchenne Muscular Dystrophy Sales by Application in 2024

5.2.7 PTC Therapeutics Duchenne Muscular Dystrophy Sales by Geographic Area in 2024

5.2.8 PTC Therapeutics Recent Developments

5.3 Pfizer

5.3.1 Pfizer Company Information

5.3.2 Pfizer Description, Business Overview

5.3.3 Pfizer Duchenne Muscular Dystrophy Products Offered

5.3.4 Pfizer Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2020-2025)

5.3.5 Pfizer Duchenne Muscular Dystrophy Sales by Product in 2024

5.3.6 Pfizer Duchenne Muscular Dystrophy Sales by Application in 2024

5.3.7 Pfizer Duchenne Muscular Dystrophy Sales by Geographic Area in 2024

5.3.8 Pfizer Recent Developments

5.4 Bristol-Myers Squibb

5.4.1 Bristol-Myers Squibb Company Information

5.4.2 Bristol-Myers Squibb Description, Business Overview

5.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Products Offered

5.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2020-2025)

5.4.5 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales by Product in 2024

5.4.6 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales by Application in 2024

5.4.7 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales by Geographic Area in 2024

5.4.8 Bristol-Myers Squibb Recent Developments

5.5 Italfarmaco

5.5.1 Italfarmaco Company Information

5.5.2 Italfarmaco Description, Business Overview

5.5.3 Italfarmaco Duchenne Muscular Dystrophy Products Offered

5.5.4 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2020-2025)

5.5.5 Italfarmaco Duchenne Muscular Dystrophy Sales by Product in 2024

5.5.6 Italfarmaco Duchenne Muscular Dystrophy Sales by Application in 2024

5.5.7 Italfarmaco Duchenne Muscular Dystrophy Sales by Geographic Area in 2024

5.5.8 Italfarmaco Recent Developments

5.6 Santhera Pharmaceuticals

5.6.1 Santhera Pharmaceuticals Company Information

5.6.2 Santhera Pharmaceuticals Description, Business Overview

5.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Products Offered

5.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2020-2025)

5.6.5 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales by Product in 2024

5.6.6 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales by Application in 2024

5.6.7 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales by Geographic Area in 2024

5.6.8 Santhera Pharmaceuticals Recent Developments

6 North America

6.1 North America Duchenne Muscular Dystrophy Market Size YoY Growth 2020-2031

6.2 North America Duchenne Muscular Dystrophy Market Facts & Figures by Country

6.2.1 North America Duchenne Muscular Dystrophy Sales by Country (2020-2031)

6.2.2 North America Duchenne Muscular Dystrophy Revenue by Country (2020-2031)

6.3 North America Duchenne Muscular Dystrophy Sales by Type (2020-2025)

6.4 North America Duchenne Muscular Dystrophy Sales by Application (2020-2025)

7 Asia-Pacific

7.1 Asia-Pacific Duchenne Muscular Dystrophy Market Size YoY Growth 2020-2031

7.2 Asia-Pacific Duchenne Muscular Dystrophy Market Facts & Figures by Region

7.2.1 Asia-Pacific Duchenne Muscular Dystrophy Sales by Region (2020-2031)

7.2.2 Asia-Pacific Duchenne Muscular Dystrophy Revenue by Region (2020-2031)

7.3 Asia-Pacific Duchenne Muscular Dystrophy Sales by Type (2020-2025)

7.4 Asia-Pacific Duchenne Muscular Dystrophy Sales by Application (2020-2025)

8 Europe

8.1 Europe Duchenne Muscular Dystrophy Market Size YoY Growth 2020-2031

8.2 Europe Duchenne Muscular Dystrophy Market Facts & Figures by Country

8.2.1 Europe Duchenne Muscular Dystrophy Sales by Country (2020-2031)

8.2.2 Europe Duchenne Muscular Dystrophy Revenue by Country (2020-2031)

8.3 Europe Duchenne Muscular Dystrophy Sales by Type (2020-2025)

8.4 Europe Duchenne Muscular Dystrophy Sales by Application (2020-2025)

9 Latin America

9.1 Latin America Duchenne Muscular Dystrophy Market Size YoY Growth 2020-2031

9.2 Latin America Duchenne Muscular Dystrophy Market Facts & Figures by Country

9.2.1 Latin America Duchenne Muscular Dystrophy Sales by Country (2020-2031)

9.2.2 Latin America Duchenne Muscular Dystrophy Revenue by Country (2020-2031)

9.3 Latin America Duchenne Muscular Dystrophy Sales by Type (2020-2025)

9.4 Latin America Duchenne Muscular Dystrophy Sales by Application (2020-2025)

10 Middle East and Africa

10.1 Latin America Duchenne Muscular Dystrophy Market Size YoY Growth 2020-2031

10.2 Middle East and Africa Duchenne Muscular Dystrophy Market Facts & Figures by Country

10.2.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2020-2031)

10.2.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2020-2031)

10.3 Middle East and Africa Duchenne Muscular Dystrophy Sales by Type (2020-2025)

10.4 Middle East and Africa Duchenne Muscular Dystrophy Sales by Application (2020-2025)

11 Supply Chain and Sales Channel analysis

11.1 Duchenne Muscular Dystrophy Supply Chain Analysis

11.2 Duchenne Muscular Dystrophy Key Raw Materials and Upstream Suppliers

11.3 Duchenne Muscular Dystrophy Clients Analysis

11.4 Duchenne Muscular Dystrophy Sales Channel and Sales Model Analysis

11.4.1 Duchenne Muscular Dystrophy Distribution Channel Analysis: Indirect Sales VS Direct Sales

11.4.2 Duchenne Muscular Dystrophy Distribution Channel Analysis: Online Sales VS Offline Sales

11.4.3 Duchenne Muscular Dystrophy Distributors

12 Duchenne Muscular Dystrophy Market Dynamics

12.1 Duchenne Muscular Dystrophy Industry Trends

12.2 Duchenne Muscular Dystrophy Market Drivers

12.3 Duchenne Muscular Dystrophy Market Challenges

12.4 Duchenne Muscular Dystrophy Market Restraints

13 Research Findings and Conclusion

14 Appendix

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.1.1 Research Programs/Design

14.1.1.2 Market Size Estimation

14.1.1.3 Market Breakdown and Data Triangulation

14.1.2 Data Source

14.1.2.1 Secondary Sources

14.1.2.2 Primary Sources

14.2 Author Details

14.3 Disclaimer

FEATURED COMPANIES

PTC Therapeutics

Sarepta Therapeutics

Pfizer Inc

Bristol–Myers Squibb

Italfarmaco S.p.A.

Santhera Pharmaceuticals

List of Tables

Table 1. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Global Duchenne Muscular Dystrophy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 3. Global Duchenne Muscular Dystrophy Market Size by Region (US$ Million): 2024 VS 2031

Table 4. Global Duchenne Muscular Dystrophy Sales by Region (2020-2025) & (K Doses)

Table 5. Global Duchenne Muscular Dystrophy Sales Forecast by Region (2026-2031) & (K Doses)

Table 6. Global Duchenne Muscular Dystrophy Revenue by Region (2020-2025) & (US$ Million)

Table 7. Global Duchenne Muscular Dystrophy Revenue Forecast by Region (2026-2031) & (US$ Million)

Table 8. Global Duchenne Muscular Dystrophy Sales Volume by Type (2020-2025) & (K Doses)

Table 9. Global Duchenne Muscular Dystrophy Sales Volume by Type (2026-2031) & (K Doses)

Table 10. Global Duchenne Muscular Dystrophy Revenue by Type (2020-2025) & (US$ Million)

Table 11. Global Duchenne Muscular Dystrophy Revenue Forecast by Type (2026-2031) & (US$ Million)

Table 12. Global Duchenne Muscular Dystrophy Sales Volume by Application (2020-2025) & (K Doses)

Table 13. Global Duchenne Muscular Dystrophy Sales Volume by Application (2026-2031) & (K Doses)

Table 14. Global Duchenne Muscular Dystrophy Revenue by Application (2020-2025) & (US$ Million)

Table 15. Global Duchenne Muscular Dystrophy Revenue by Application (2026-2031) & (US$ Million)

Table 16. Global Duchenne Muscular Dystrophy Sales by Manufacturer (2020-2025) & (K Doses)

Table 17. Global Duchenne Muscular Dystrophy Sales Share by Manufacturer (2020-2025)

Table 18. Duchenne Muscular Dystrophy Revenue by Manufacturer (2020-2025) & (US$ Million)

Table 19. Duchenne Muscular Dystrophy Revenue Share by Manufacturer (2020-2025)

Table 20. Key Manufacturers Duchenne Muscular Dystrophy Price (2020-2025) & (USD/Dose)

Table 21. Ranking of Global Top Duchenne Muscular Dystrophy Manufacturers by Revenue (US$ Million) in 2024

Table 22. Global Duchenne Muscular Dystrophy Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)

Table 23. Global Duchenne Muscular Dystrophy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy as of 2024)

Table 24. Duchenne Muscular Dystrophy Manufacturers Manufacturing Base Distribution and Headquarters

Table 25. Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Market

Table 26. Manufacturers Duchenne Muscular Dystrophy Product Type and Application

Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 28. Sarepta Therapeutics Company Information

Table 29. Sarepta Therapeutics Description and Business Overview

Table 30. Sarepta Therapeutics Duchenne Muscular Dystrophy Product

Table 31. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 32. Sarepta Therapeutics Sales Proportion of Duchenne Muscular Dystrophy by Product in 2024

Table 33. Sarepta Therapeutics Sales Proportion of Duchenne Muscular Dystrophy by Application in 2024

Table 34. Sarepta Therapeutics Sales Proportion of Duchenne Muscular Dystrophy by Geographic Area in 2024

Table 35. Sarepta Therapeutics Recent Developments

Table 36. PTC Therapeutics Company Information

Table 37. PTC Therapeutics Description and Business Overview

Table 38. PTC Therapeutics Duchenne Muscular Dystrophy Product

Table 39. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 40. PTC Therapeutics Sales Proportion of Duchenne Muscular Dystrophy by Product in 2024

Table 41. PTC Therapeutics Sales Proportion of Duchenne Muscular Dystrophy by Application in 2024

Table 42. PTC Therapeutics Sales Proportion of Duchenne Muscular Dystrophy by Geographic Area in 2024

Table 43. PTC Therapeutics Recent Developments

Table 44. Pfizer Company Information

Table 45. Pfizer Description and Business Overview

Table 46. Pfizer Duchenne Muscular Dystrophy Product

Table 47. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 48. Pfizer Sales Proportion of Duchenne Muscular Dystrophy by Product in 2024

Table 49. Pfizer Sales Proportion of Duchenne Muscular Dystrophy by Application in 2024

Table 50. Pfizer Sales Proportion of Duchenne Muscular Dystrophy by Geographic Area in 2024

Table 51. Pfizer Recent Developments

Table 52. Bristol-Myers Squibb Company Information

Table 53. Bristol-Myers Squibb Description and Business Overview

Table 54. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product

Table 55. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 56. Bristol-Myers Squibb Sales Proportion of Duchenne Muscular Dystrophy by Product in 2024

Table 57. Bristol-Myers Squibb Sales Proportion of Duchenne Muscular Dystrophy by Application in 2024

Table 58. Bristol-Myers Squibb Sales Proportion of Duchenne Muscular Dystrophy by Geographic Area in 2024

Table 59. Bristol-Myers Squibb Recent Developments

Table 60. Italfarmaco Company Information

Table 61. Italfarmaco Description and Business Overview

Table 62. Italfarmaco Duchenne Muscular Dystrophy Product

Table 63. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 64. Italfarmaco Sales Proportion of Duchenne Muscular Dystrophy by Product in 2024

Table 65. Italfarmaco Sales Proportion of Duchenne Muscular Dystrophy by Application in 2024

Table 66. Italfarmaco Sales Proportion of Duchenne Muscular Dystrophy by Geographic Area in 2024

Table 67. Italfarmaco Recent Developments

Table 68. Santhera Pharmaceuticals Company Information

Table 69. Santhera Pharmaceuticals Description and Business Overview

Table 70. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product

Table 71. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)

Table 72. Santhera Pharmaceuticals Sales Proportion of Duchenne Muscular Dystrophy by Product in 2024

Table 73. Santhera Pharmaceuticals Sales Proportion of Duchenne Muscular Dystrophy by Application in 2024

Table 74. Santhera Pharmaceuticals Sales Proportion of Duchenne Muscular Dystrophy by Geographic Area in 2024

Table 75. Santhera Pharmaceuticals Recent Developments

Table 76. North America Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)

Table 77. North America Duchenne Muscular Dystrophy Sales by Country (2026-2031) & (K Doses)

Table 78. North America Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & (US$ Million)

Table 79. North America Duchenne Muscular Dystrophy Revenue by Country (2026-2031) & (US$ Million)

Table 80. North America Duchenne Muscular Dystrophy Sales by Type (2020-2025) & (K Doses)

Table 81. North America Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)

Table 82. Asia-Pacific Duchenne Muscular Dystrophy Sales by Region (2020-2025) & (K Doses)

Table 83. Asia-Pacific Duchenne Muscular Dystrophy Sales by Region (2026-2031) & (K Doses)

Table 84. Asia-Pacific Duchenne Muscular Dystrophy Revenue by Region (2020-2025) & (US$ Million)

Table 85. Asia-Pacific Duchenne Muscular Dystrophy Revenue by Region (2026-2031) & (US$ Million)

Table 86. Asia-Pacific Duchenne Muscular Dystrophy Sales by Type (2020-2025) & (K Doses)

Table 87. Asia-Pacific Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)

Table 88. Europe Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)

Table 89. Europe Duchenne Muscular Dystrophy Sales by Country (2026-2031) & (K Doses)

Table 90. Europe Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & (US$ Million)

Table 91. Europe Duchenne Muscular Dystrophy Revenue by Country (2026-2031) & (US$ Million)

Table 92. Europe Duchenne Muscular Dystrophy Sales by Type (2020-2025) & (K Doses)

Table 93. Europe Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)

Table 94. Latin America Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)

Table 95. Latin America Duchenne Muscular Dystrophy Sales by Country (2026-2031) & (K Doses)

Table 96. Latin America Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & (US$ Million)

Table 97. Latin America Duchenne Muscular Dystrophy Revenue by Country (2026-2031) & (US$ Million)

Table 98. Latin America Duchenne Muscular Dystrophy Sales by Type (2020-2025) & (K Doses)

Table 99. Latin America Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)

Table 100. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2020-2025) & (K Doses)

Table 101. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2026-2031) & (K Doses)

Table 102. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2020-2025) & (US$ Million)

Table 103. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2026-2031) & (US$ Million)

Table 104. Middle East and Africa Duchenne Muscular Dystrophy Sales by Type (2020-2025) & (K Doses)

Table 105. Middle East and Africa Duchenne Muscular Dystrophy Sales by Application (2020-2025) & (K Doses)

Table 106. Duchenne Muscular Dystrophy Key Raw Materials, Industry Status and Trend

Table 107. Duchenne Muscular Dystrophy Key Raw Materials and Upstream Suppliers

Table 108. Duchenne Muscular Dystrophy Clients Status and Trend

Table 109. Duchenne Muscular Dystrophy Typical Clients

Table 110. Duchenne Muscular Dystrophy Distributors

Table 111. Duchenne Muscular Dystrophy Market Trends

Table 112. Duchenne Muscular Dystrophy Market Drivers

Table 113. Duchenne Muscular Dystrophy Market Challenges

Table 114. Duchenne Muscular Dystrophy Market Restraints

Table 115. Research Programs/Design for This Report

Table 116. Key Data Information from Secondary Sources

Table 117. Key Data Information from Primary Sources

Table 118. QYR Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Duchenne Muscular Dystrophy Product Picture

Figure 2. Global Duchenne Muscular Dystrophy Market Size by Type (US$ Million): 2020 VS 2024 VS 2031

Figure 3. Global Duchenne Muscular Dystrophy Sales Market Share by Type in 2024 & 2031

Figure 4. Exondys 51 Product Picture

Figure 5. Emflaza Product Picture

Figure 6. Translarna Product Picture

Figure 7. Global Duchenne Muscular Dystrophy Market Size by Application (US$ Million): 2020 VS 2024 VS 2031

Figure 8. Global Duchenne Muscular Dystrophy Sales Market Share by Application in 2024 & 2031

Figure 9. Hospitals

Figure 10. Clinics

Figure 11. Home Care

Figure 12. Duchenne Muscular Dystrophy Report Years Considered

Figure 13. Global Duchenne Muscular Dystrophy Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Duchenne Muscular Dystrophy Market Size 2020-2031 (US$ Million)

Figure 15. Global Duchenne Muscular Dystrophy Sales 2020-2031 (K Doses)

Figure 16. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Region (2020-2031)

Figure 17. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2020-2031)

Figure 18. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Type (2020-2031)

Figure 19. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by Type (2020-2031)

Figure 20. Duchenne Muscular Dystrophy Average Selling Price (ASP) by Type (2020-2025) & (USD/Dose)

Figure 21. Global Duchenne Muscular Dystrophy Sales Market Share Forecast by Application (2020-2031)

Figure 22. Global Duchenne Muscular Dystrophy Revenue Market Share Forecast by Application (2020-2031)

Figure 23. Duchenne Muscular Dystrophy Average Selling Price (ASP) by Application (2020-2025) & (USD/Dose)

Figure 24. Exondys 51 of Duchenne Muscular Dystrophy Revenue Market Share by Application, 2024 VS 2031

Figure 25. Emflaza of Duchenne Muscular Dystrophy Revenue Market Share by Application, 2024 VS 2031

Figure 26. Translarna of Duchenne Muscular Dystrophy Revenue Market Share by Application, 2024 VS 2031

Figure 27. Global Duchenne Muscular Dystrophy Sales Share by Manufacturer in 2024

Figure 28. Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 29. Exondys 51 Market Sales Proportion by Manufacturer in 2024

Figure 30. Emflaza Market Sales Proportion by Manufacturer in 2024

Figure 31. Translarna Market Sales Proportion by Manufacturer in 2024

Figure 32. North America Duchenne Muscular Dystrophy Revenue 2020-2031 (US$ Million)

Figure 33. North America Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2025)

Figure 34. North America Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)

Figure 35. Asia-Pacific Duchenne Muscular Dystrophy Revenue 2020-2031 (US$ Million)

Figure 36. Asia-Pacific Duchenne Muscular Dystrophy Sales Market Share by Region (2020-2031)

Figure 37. Asia-Pacific Duchenne Muscular Dystrophy Revenue Market Share by Region (2020-2031)

Figure 38. Asia-Pacific Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2025)

Figure 39. Asia-Pacific Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)

Figure 40. Europe Duchenne Muscular Dystrophy Revenue Growth Rate 2020-2031 (US$ Million)

Figure 41. Europe Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2031)

Figure 42. Europe Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2031)

Figure 43. Europe Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2025)

Figure 44. Europe Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)

Figure 45. Latin America Duchenne Muscular Dystrophy Revenue Growth Rate 2020-2031 (US$ Million)

Figure 46. Latin America Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2031)

Figure 47. Latin America Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2025)

Figure 48. Latin America Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2025)

Figure 49. Latin America Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)

Figure 50. Middle East and Africa Duchenne Muscular Dystrophy Revenue Growth Rate 2020-2031 (US$ Million)

Figure 51. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Country (2020-2031)

Figure 52. Middle East and Africa Duchenne Muscular Dystrophy Revenue Market Share by Country (2020-2031)

Figure 53. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Type (2020-2025)

Figure 54. Middle East and Africa Duchenne Muscular Dystrophy Sales Market Share by Application (2020-2025)

Figure 55. Duchenne Muscular Dystrophy Supply Chain (Upstream and Downstream Market)

Figure 56. Global Production Market Share of Duchenne Muscular Dystrophy Raw Materials by Region in 2024

Figure 57. Duchenne Muscular Dystrophy Distribution Channels

Figure 58. Global Duchenne Muscular Dystrophy Percentage 2020-2031: Indirect Sales VS Direct Sales

Figure 59. Global Duchenne Muscular Dystrophy Percentage 2020-2031: Online Sales VS Offline Sales

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$5900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$8850

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$11800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Drugs for Duchenne Muscular Dystrophy DMD Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Myotonic Dystrophy Drug Market Research Report 2024

Myotonic Dystrophy Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Myotonic Dystrophy Treatment Market Research Report 2025

Myotonic Dystrophy Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Spinal Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Duchenne Muscular Dystrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Myasthenia Gravis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Myasthenia Gravis Therapies Market Research Report 2024

Global Spinal Muscular Atrophy SMA Treatment Market Research Report 2024

Global Becker Muscular Dystropy Market Research Report 2025

Global Sarcopenia Treatments Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030

Adrenoleukodystrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Sarcopenia Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Myotonic Muscular Dystrophy DMD Treatments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Dystrophin Market Research Report 2024

Global Ophthalmology Disorders Drug Market Insights Forecast to 2030

Spinal Muscular Atrophy SMA Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Spinal and Bulbar Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions